23 April 2025
: Case report 
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights
Unusual or unexpected effect of treatment
Renwei Huang
EF 1, Yuhe Yin EF 1, Zewen Zhao EF 1, Xiaoying Dong BC 1, Chao Chen B 2, Haowen Lin BC 1,3, Yiming Tao BC 1, Siqi Peng BC 1, Sichun Wen BC 1, Bohou Li BC 1, Qiong Wu D 1, Sijia Li D 1, Ting Lin D 1, Hao Dai D 1, Feng Wen D 1, Zhuo Li D 1, Lixia Xu D 1, Jianchao Ma D 1*, Shuangxin Liu AG 1, Zhonglin Feng A 1
DOI: 10.12659/AJCR.946727
Am J Case Rep 2025; 26:e946727
Figure 1. Results of renal biopsy pathology. (A) Immunofluorescence staining indicates weak positivity for PLA2R. (B) Masson staining, the red arrow shows subepithelial eosinophilic deposition. (C) PASM staining, the blue thin arrow indicates a peg-like structure. (D) Electron microscopy, the blue bold arrow indicates the deposition of electron-dense material. PLA2R – phospholipase A2 receptor.